Phase III Sativex® Data Published in Leading Neurology Journal
Phase III Sativex® Data Published in Leading Neurology Journal
28 February 2007
GW Pharmaceuticals plc (AIM: GWP) a leading neurology journal, The European Journal of Neurology, today reports a study showing that Sativex significantly reduces intractable spasticity (spasms and stiffness) in people with Multiple Sclerosis (MS).
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Nulla placerat, nulla ut tincidunt luctus, quam tellus rhoncus odio, vel tincidunt leo nulla bibendum odio. Lorem ipsum dolor sit amet, consectetuer adipiscing elit.